

CS Pharmaceuticals announces strategic investment by Downing Ventures

London, England, November 22, 2021, CS Pharmaceuticals Ltd. (CSP), a British speciality pharmaceutical company focused on first- and best-in-class speciality therapeutics and treatments for rare diseases in China, are pleased to announce an investment by Downing Ventures.

“We are delighted to welcome Downing Ventures to the CSP shareholder register. Downing has a strong track record of investing in innovative companies and managing assets that positively impact society which is a perfect fit with CSP’s business model” said Darren Mercer CEO at CSP.

“CSP was established in the UK and has a strong presence in China (in Shanghai and Beijing). This gives the company a unique position compared to competitors typically founded in China. Partners can deal with an expert Anglo/Chinese team - fluent in English, based in the UK and with a team on the ground in China. The contracts are established under UK law, with quality and compliance standards expected in the West. With this in mind, CSP has established itself as a trusted partner for China. This unique setup looks set to increase the likelihood of successful deal-making with Western partners. It soothes concerns about dealing directly with Chinese companies who may not share Western compliance processes, IP protection or financial transparency. We are delighted to make an investment in CSP”, said Matt Pierce, Principal at Downing LLP.

About CS Pharmaceuticals

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a ‘go-to’ trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China.

www.cspharmaceuticals.com

Contacts

CS Pharmaceuticals
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691

